Search clinical trials for: CS3005

Total 137 results

PharmaKing

Completed

Efficacy and Safety of PMK-S005 in the Prevention of Recurrent Peptic Ulcer in Low-dose Aspirin Users

Peptic Ulcer

Korea, Republic of
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Recruiting

Evaluate the Preliminary Efficacy, Safety, and PK of Subcutaneous JS005 in Chinese Adult Patients With Active AS

Active Ankylosing Spondylitis

China
Xspray Pharma AB

Completed

Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male Subjects

Pharmacokinetics | Bioavailability

United Kingdom
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
The First Affiliated Hospital of Nanchang University; Chinese PLA General Hospital and other collaborators

Not yet recruiting

Evaluate the Safety and Effectiveness of the Endoscopic Surgical Instrument Control System (SP1000).

Urologic Neoplasms

China
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis

Switzerland
Tianjin Medical University Cancer Institute and...

Unknown

Neoadjuvant Treatment of Early Triple-negative Breast Cancer With Chidamide and Chemotherapy

Triple-negative Breast Cancer

China
Chipscreen Biosciences, Ltd.

Completed

Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma

Non-hodgkin's Lymphoma

China
Medical University of Vienna

Completed

Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes. (LUDOC)

Ovarian Epithelial Cancer

Austria, Germany, Belgium, Czechia
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

Moderate to Severe Chronic Plaque Psoriasis

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Phase I Study of Comparing Single Dose JS005 (Recombinant Humanized Monoclonal Antibody Against IL-17A) With Placebo in Tolerability, Safety, Immunogenicity and Pharmacokinetic in Healthy Volunteers

Tolerability, Safety, Immunogenicity and Pharmacokinetic of JS005

China
CStone Pharmaceuticals

Active, not recruiting

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

Unresectable Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

China
Ginekologija Dr. Franić, D.O.O.

Active, not recruiting

RF in the Treatment OAB in UUI- a Prospective Randomized Placebo Controlled Study (RFandOAB)

Urge Incontinence | Overactive Bladder Syndrome

Slovenia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers

Metastatic Clear Cell Renal Cell Carcinoma | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Stage IVA Prostate Cancer AJCC v8 | Stage... and other conditions

United States
HUYABIO International, LLC.

Completed

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

United States
Chipscreen Biosciences, Ltd.

Completed

Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer

Non-small-cell Lung Cancer

China
National Cancer Institute (NCI)

Completed

Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Human Papillomavirus Infection | Stage IVB Cervical Cancer AJCC v6 and v7

United States, Canada
Daiichi Sankyo, Inc.

Completed

Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer

Pancreatic Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Recruiting

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Metastatic Clear Cell Renal Cell Carcinoma | Advanced Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia

Previously Treated Myelodysplastic Syndrome | Secondary Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia,...

United States
National Cancer Institute (NCI)

Completed

Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant

Recurrent Hodgkin Lymphoma | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Recurrent Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Plasma Cell Myeloma | Myeloproliferative Neoplasm | Recurrent... and other conditions

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors

Prognostic Stage IIIC Breast Cancer AJCC v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Melanoma | Stage IV Lung Cancer AJCC v8 | Locally Advanced Malignant Solid Neoplasm | Locally... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Ipilimumab, Ibrutinib, and Nivolumab for the Treatment of Chronic Lymphocytic Leukemia and Richter Transformation

Hematopoietic and Lymphoid Cell Neoplasm | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma

United States
Chipscreen Biosciences, Ltd.

Completed

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

China
Cytos Biotechnology AG

Completed

A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis

House Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Advanced Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Peritoneal Carcinomatosis | Malignant Peritoneal Neoplasm | Recurrent Endometrial Carcinoma | Stage IVB Uterine Corpus Cancer AJCC v8 | Recurrent Cervical Carcinoma | Metastatic Malignant Female... and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study

Hematopoietic and Lymphoid Cell Neoplasm | Lynch Syndrome | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Recurrent Primary Central Nervous System Neoplasm | Refractory Primary Central... and other conditions

United States, Canada
Peng Liu
Chipscreen Biosciences, Ltd.

Unknown

Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Multiple Myeloma

China
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Refractory Malignant Solid Neoplasm | Recurrent Melanoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Recurrent Non-Hodgkin... and other conditions

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma

Metastatic Leiomyosarcoma | Unresectable Leiomyosarcoma | Uterine Corpus Leiomyosarcoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma

United States
Emory University
National Cancer Institute (NCI)

Not yet recruiting

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
National Cancer Institute (NCI)

Completed

Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery

Stage III Soft Tissue Sarcoma AJCC v7 | Stage IV Soft Tissue Sarcoma AJCC v7 | Pleomorphic Liposarcoma | Metastatic Undifferentiated Pleomorphic Sarcoma | Metastatic Unresectable Sarcoma | Unresectable Soft Tissue Sarcoma | Metastatic Soft Tissue Sarcoma | Locally Advanced Soft Tissue Sarcoma | Metastatic... and other conditions

United States
Mayo Clinic

Active, not recruiting

Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Terminated

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | BRAF V600E Mutation Present | BRAF V600K Mutation Present | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Metastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine Carcinoma

United States, Canada
University of Washington

Completed

Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Cancers

Metastatic Malignant Neoplasm in the Bone | Salivary Gland Carcinoma | Metastatic Malignant Neoplasm in the Lung | Stage IV Major Salivary Gland Cancer AJCC v8 | Stage IVA Major Salivary Gland Cancer AJCC v8 | Stage IVB Major Salivary Gland Cancer AJCC v8 | Stage IVC Major Salivary Gland Cancer...

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma

Pleural Biphasic Mesothelioma | Pleural Sarcomatoid Mesothelioma

United States
Chipscreen Biosciences, Ltd.

Completed

Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients

Peripheral T-cell Lymphoma

China
Stanford University
National Institutes of Health (NIH)

Active, not recruiting

Serial Ultrasound in Metastatic Renal Cell Carcinoma (mRCC)

Kidney Cancer | Renal Cell Carcinoma | Metastatic Renal Cell Carcinoma

United States
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
M.D. Anderson Cancer Center

Active, not recruiting

Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma

Malignant Solid Neoplasm | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Stage III Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Unresectable Melanoma | Clinical Stage III Cutaneous... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

Lung Adenocarcinoma | Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Ipilimumab and/or Nivolumab in Combination With Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Gliosarcoma | Supratentorial Glioblastoma

United States
National Cancer Institute (NCI)

Completed

Ipilimumab, Cetuximab, and Intensity-Modulated Radiation Therapy in Treating Patients With Previously Untreated Stage III-IVB Head and Neck Cancer

Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB... and other conditions

United States

Search clinical trials for: CS3005

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Macedonia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations